Saturn V Capital Management LP
13F Reported Value
ⓘ$697.5M
Holdings
23
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Saturn V Capital Management LP disclosed 23 positions worth $697.5M in its Form 13F-HR for Q2 2026, led by $AMLX (Amylyx Pharmaceuticals, Inc.) at 11.9% of the equity portfolio, followed by $ALMS and $ABVX. During the quarter the fund opened 3 new positions and exited 1 — including a new stake in $TRVI and a full exit from $COGT. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Saturn V Capital Management LP’s Form 13F-HR filing with the SEC under CIK 1964437.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 8.7#2,731
Quality
$83.0M4,624,101 sh - 7.1#2,949
Quality
$82.0M2,915,443 sh - —
Quality
$69.1M518,865 sh - —
Quality
$49.6M852,914 sh - —
Quality
$48.0M4,658,429 sh - —
Quality
$45.4M1,314,122 sh - —
Quality
$38.8M160,938 sh - —
Quality
$38.7M370,318 sh - —
Quality
$38.4M524,730 sh - —
Quality
$34.0M3,303,686 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Amylyx Pharmaceuticals, Inc.$AMLX | 8.7#2,731 | $83.0M | 4,624,101 |
 ALUMIS INC.$ALMS | 7.1#2,949 | $82.0M | 2,915,443 |
 Abivax S.A.$ABVX | — | $69.1M | 518,865 |
 Vaxcyte, Inc.$PCVX | — | $49.6M | 852,914 |
 Immix Biopharma, Inc.$IMMX | — | $48.0M | 4,658,429 |
 Pharvaris N.V.$PHVS | — | $45.4M | 1,314,122 |
 Jazz Pharmaceuticals plc$JAZZ | — | $38.8M | 160,938 |
 Celcuity Inc.$CELC | — | $38.7M | 370,318 |
 Disc Medicine, Inc.$IRON | — | $38.4M | 524,730 |
 Candel Therapeutics, Inc.$CADL | — | $34.0M | 3,303,686 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Saturn V Capital Management LP's 23 positions.
Showing top 10 of 23 holdings.
Sector Allocation
Healthcare
$697.5M
Full Holdings — Saturn V Capital Management LP (Q2 2026)
All 23 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $AMLX | Amylyx Pharmaceuticals, Inc. | $83.0M | 11.9% | +6% | 8.7 |
| 2 | $ALMS | ALUMIS INC. | $82.0M | 11.8% | -9% | 7.1 |
| 3 | $ABVX | Abivax S.A. | $69.1M | 9.9% | -4% | — |
| 4 | $PCVX | Vaxcyte, Inc. | $49.6M | 7.1% | +3% | — |
| 5 | $IMMX | Immix Biopharma, Inc. | $48.0M | 6.9% | +26% | — |
| 6 | $PHVS | Pharvaris N.V. | $45.4M | 6.5% | +9% | — |
| 7 | $JAZZ | Jazz Pharmaceuticals plc | $38.8M | 5.6% | -1% | — |
| 8 | $CELC | Celcuity Inc. | $38.7M | 5.5% | +31% | — |
| 9 | $IRON | Disc Medicine, Inc. | $38.4M | 5.5% | +17% | — |
| 10 | $CADL | Candel Therapeutics, Inc. | $34.0M | 4.9% | +14% | — |
| 11 |  $XFOR | X4 Pharmaceuticals, Inc | $32.6M | 4.7% | +8% | 28 |
| 12 |  $MNPR | Monopar Therapeutics | $28.9M | 4.1% | -10% | — |
| 13 |  $DYN | Dyne Therapeutics, Inc. | $23.5M | 3.4% | +9% | — |
| 14 |  $TRVI | Trevi Therapeutics, Inc. | $19.6M | 2.8% | NEW | — |
| 15 |  $ZURA | Zura Bio Ltd | $12.4M | 1.8% | +184% | — |
| 16 |  $SGMT | Sagimet Biosciences Inc. | $11.4M | 1.6% | NEW | — |
| 17 |  $OCS | Oculis Holding AG | $9.5M | 1.4% | +33% | — |
| 18 |  $IKT | Inhibikase Therapeutics, Inc. | $7.9M | 1.1% | +0% | — |
| 19 |  $VIR | Vir Biotechnology, Inc. | $7.9M | 1.1% | NEW | 38.2 |
| 20 |  $IVVD | Invivyd, Inc. | $7.3M | 1.1% | -23% | 29.7 |
| 21 |  $ANRO | Alto Neuroscience, Inc. | $4.8M | 0.7% | +105% | — |
| 22 |  $MSLE | Satellos Bioscience Inc. | $2.7M | 0.4% | +0% | — |
| 23 |  $OVID | Ovid Therapeutics Inc. | $1.8M | 0.3% | -84% | 26.4 |
New Positions (3)
Exited Positions (1)
$COGT Cogent Biosciences, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Saturn V Capital Management LP including:
Track Saturn V Capital Management LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Saturn V Capital Management LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Saturn V Capital Management LP
13F Pro is an AI hedge fund tracker and stock research platform. For Saturn V Capital Management LP (SEC CIK: 1964437), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Saturn V Capital Management LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.